Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scott_jiminez who started this subject	9/27/2000 8:41:58 PM
From: scott_jiminez	of 278

Earlier today I made the statement, 'One could only hope that other neurological diseases, specifically the neurodegenerative class, can also be attenuated by interfering with cytokines and other potentially toxic mediators released during chronic inflammation. ' [http://www.siliconinvestor.com/readmsg.aspx?msgid=14462770] In this week's J. Neurosci additional evidence is presented showing that the diminution of at least one arm of an inflammatory response common during Alzheimer's Disease (AD) can have important effects jneurosci.org. Thus activating cellular PPAR g with specific agonists - and many NSAIDS fall into this class - can significantly diminish iNOS (i.e. nitric oxide) activation/expression and thus attenuate cell death. Thus the correlational data extant that aspirin, ibuprofen, etc. can provide protection against the progression of AD is further substantiated. Perhaps in a very real sense it's time for us boomers to consider seriously an NSAID a day. [Note - the NS398 mentioned in the article is a specific COX-2 inhibitor (i.e similar to Vioxx or Celebrex). Thus the broader spectrum NSAIDs - at least broader in the COX specificity sense - are required for the observed protection]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next